Document:

exv10w1

 

Exhibit 10.1

February 23, 2007

Dear David:

     We are pleased to offer you a position with McAfee, Inc. (the “Company”) as President and
Chief Executive Officer reporting to the Company’s Board of Directors (the “Board”). Your
employment with the Company in such position will commence on or prior to April 2, 2007. As of the
date your employment with the Company commences (the “Employment Commencement Date”), you agree to
render such business and professional services in the performance of your duties, consistent with
your title and position within the Company, as will reasonably be assigned to you by the Board, as
well as any other reasonable duties assigned to you by the Board. You and the Company agree that
your employment with the Company constitutes “at-will” employment and this employment relationship
may be terminated at any time, upon written notice to the other party, with or without good cause
or for any or no cause, at the option either of you or the Company. The period you are employed by
the Company is referred to herein as the “Employment Term.”

     During the Employment Term, you agree to devote your full business efforts and time to the
Company and will use good faith efforts to discharge your obligations to the best of your ability
and in accordance with the Company’s written guidelines and policies. For the duration of the
Employment Term, you agree not to actively engage in any other employment, occupation, or
consulting activity for any direct or indirect remuneration without the prior approval of the Board
or its Compensation Committee (the “Compensation Committee”). You shall be permitted to continue
serving on the board of directors (and committees thereof) of Polycom, Inc.; provided, however,
that service on any other board of directors or advisory committees shall only be permitted with
the prior consent of the Board.

     You will be appointed to serve as a member of the Board as of the Employment Commencement
Date, and agree to serve as a Board member without additional compensation. During the Employment
Term, at each annual meeting of the Company’s stockholders at which your term as a member of the
Board has expired, the Company will nominate you to serve as a member of the Board. Your service
as a member of the Board will be subject to any required stockholder approval. Upon the
termination of your employment for any reason, unless otherwise requested by the Board, you will be
deemed to have resigned from the Board voluntarily as of the end of your employment and at the
Board’s request, you agree to execute any documents necessary to reflect your resignation.

     The Company will pay you an annual salary of $900,000 as compensation for your services (the
“Base Salary”). Your Base Salary will be subject to annual review by the Board or

 

 

Compensation Committee for possible increases, but may only be decreased with your consent. You
will also be eligible to receive an annual target bonus equal to $1,000,000 (the “Target Bonus”).
The actual bonus you will receive, if any, will depend upon the extent to which the applicable
performance goal(s) specified by the Board or the Committee are achieved or exceeded. Your earned
bonus for fiscal year 2007 will be no less than $600,000. Any bonus earned pursuant to this offer
letter agreement will be paid to you within two and one-half months of the completion of the fiscal
year during which the bonus was earned.

     You will be eligible to participate in all Company employee benefit plans, policies and
arrangements that are applicable to other senior executive officers of the Company. You will be
entitled to receive paid annual vacation with vacation accrual of not less than twenty (20) days
per year in accordance with Company policy. The Company will reimburse you for reasonable travel
and other business expenses incurred by you in the furtherance of your duties to the Company, in
accordance with the Company’s expense reimbursement policy. You shall be permitted to fly in
business class when traveling on Company business, or first class if business class is unavailable.

     As a condition of your employment, you agree to relocate your primary residence to the
Dallas-Fort Worth area within six (6) months of the Employment Commencement Date. In connection
with this relocation, the Company will reimburse your reasonable expenses relating to the
following: (i) the transaction costs incurred by you relating to the purchase of a residence in the
Dallas-Fort Worth area; (ii) the transaction costs incurred by you relating to the sale of your
real estate properties in California up to a maximum of $300,000; (iii) the costs associated with
moving your household goods and personal items to the Dallas-Fort Worth area, and (iv) the costs
associated with up to three (3) trips by you and your family to the Dallas-Fort Worth area to
secure housing in the Dallas-Fort Worth area. In addition, for the earlier of six (6) months from
the Employment Commencement Date or the date you and your family have established your primary
residence in the Dallas-Fort Worth area, the Company will reimburse you for: (i) your reasonable
temporary housing costs in the Dallas-Fort Worth area, and (ii) your reasonable expenses for weekly
round-trip airfare to California.

     The Company will grant you an option to purchase 500,000 shares of the Company’s stock (the
“Option”). The Company will grant the option in accordance with its current and customary practice
which would be part of its normal compensation committee meetings at the next quarterly board
meeting. The exercise price of the Option will equal 100% of the fair market value of the
Company’s common stock on the date of grant. The Option will be scheduled to vest as follows: 25%
of the shares subject to the Option will vest on the first anniversary of the grant and 1/48 of the
shares originally subject to the Option will be scheduled to vest monthly thereafter assuming your
continued service with the Company on each scheduled vesting date, so as to be 100% vested on the
fourth anniversary of the grant. The Option grant will be contingent on your executing the
Company’s standard stock option agreement and will be subject to the terms and conditions of the
1997 Stock Incentive Plan (the “Plan”). Your ability to exercise the Option, however, will be
delayed until such time as the Company’s S-8 registration statement covering shares issuable under
the Plan becomes effective (the “S-8 Effective Date”).

 

 

     Additionally, within one (1) week after the S-8 Effective Date, the Company will grant you
125,000 stock units (the “First Stock Unit Grant”). The First Stock Unit Grant will be scheduled
to vest as follows: (i) one-third of the stock units will vest on the first anniversary of the
Employment Commencement Date; (ii) one-third of the stock units will vest on the second anniversary
of the Employment Commencement Date, and (iii) one-third of the stock units will vest on the third
anniversary of the Employment Commencement Date, assuming your continued service with the Company
through each scheduled vesting date. The First Stock Unit Grant will be contingent on your
executing the Company’s standard stock unit agreement and will be subject to the terms and
conditions of the Plan.

     Within one (1) week after the S-8 Effective Date, the Company will grant you an additional
125,000 stock units (the “Second Stock Unit Grant”). The Second Stock Unit Grant will vest as
follows: (i) one-third of the stock units will vest two business days following the Company’s
public disclosure of earnings relating to the quarter ending in the first anniversary of the
Employment Commencement Date; (ii) one-third of the stock units will vest two business days
following the Company’s public disclosure of earnings relating to the quarter ending in the second
anniversary of the Employment Commencement Date; and, (iii) one-third of the stock units will vest
two business days following the Company’s public disclosure of earnings relating to the quarter
ending in the third anniversary of the Employment Commencement Date, assuming your continued
service with the Company through each scheduled vesting date, and subject, in each case, to the
Company meeting specific qualitative and quantitative pro forma earnings per share and other
milestones, with the specific pro forma earnings per share and other milestones to be determined by
the Compensation Committee of the Board, following consultation with you, no later than the end of
the period required to qualify such grant as performance-based compensation under Internal Revenue
Code Section 162(m). Such pre-established, objective performance milestones will include, among
other criteria, specific standards relating to the correlation between partial milestone
achievement and partial vesting, cumulative milestone achievement and possible catch up vesting and
acceleration of vesting if certain milestones are exceeded. To the extent Second Stock Unit Grant
does not vest, it shall be forfeited. The Second Stock Unit Grant will be contingent on your
executing the Company’s standard stock unit agreement and will be subject to the terms and
conditions of the Plan.

     You will be eligible to receive additional equity grants on an annual basis consistent with
the normal compensation practices of the Company.

     If your employment is terminated by the Company without Cause or if you resign for Good
Reason, then subject to your executing and not revoking a release of claims in a form satisfactory
to the Company (a “Release”), you will receive, less applicable tax withholdings: (i) a lump sum
payment equal to your Base Salary; (ii) a lump sum payment equal to the current year’s Target
Bonus; (iii) accelerated vesting on the next unvested tranche of the First Stock Unit Grant; and
(iv) reimbursement for premiums paid for continued health benefits for you and your covered
dependents under the Company’s health plans for twelve (12) months, payable when such premiums are
due (provided you validly elect to continue coverage under the Consolidated Omnibus Budget
Reconciliation Act (“COBRA”)). Severance payments and benefits may be delayed in order to comply
with the provisions of Internal Revenue Code Section 409A and the proposed or final regulations
issued thereunder. No severance or other

 

 

     benefits pursuant to this offer letter agreement will be paid or provided until the Release becomes effective.

     If your employment is terminated by the Company without Cause or if you resign for Good
Reason, and such termination occurs within twelve (12) months following a Change of Control, then
subject to your executing and not revoking a Release, you will receive, less applicable tax
withholdings: (i) a lump sum payment equal to your Base Salary; (ii) a lump sum payment equal to
the current year’s Target Bonus; (iii) accelerated vesting on the Option equal to the greater of
(A) twelve (12) months accelerated vesting, or (B) 50% of the then unvested shares accelerated
vesting, and (iv) reimbursement for premiums paid for continued health benefits for you and your
covered dependents under the Company’s health plans for twelve (12) months, payable when such
premiums are due (provided you validly elect to continue coverage under COBRA). Severance payments
and benefits may be delayed in order to comply with the provisions of Internal Revenue Code Section
409A and the proposed or final regulations issued thereunder. No severance or other benefits
pursuant to this offer letter agreement will be paid or provided until the Release becomes
effective.

     For the purposes of this offer letter agreement, “Cause” will be defined as a termination of
your employment, based upon a good faith determination of the Board, for any of the following
reasons: (i) any act of misconduct or dishonesty by you in the performance of your duties under
this offer letter agreement; (ii) any willful failure by you to attend to your duties specified
under this offer letter agreement; (iii) your material breach of this offer letter agreement after
(with respect to curable material breaches only) there has been delivered to you a written demand
for performance from the Board which describes the basis for the Board’s belief that you have
materially breached your obligations under this offer letter agreement and you have not taken
corrective action with regard to any such material breach within thirty (30) days receiving such
written demand; (iv) your conviction of (or pleading guilty or nolo contendere to) any felony or
misdemeanor involving theft, embezzlement, dishonesty or moral turpitude, or (v) your
unsatisfactory performance of your duties as determined by the Board, after there has been
delivered to you a written demand for performance from the Board which describes the basis for the
Board’s belief that you have not satisfactorily performed your duties and you have not taken
adequate corrective action within thirty (30) days of receiving such written demand.

     For the purposes of this offer letter agreement, “Change of Control” will have the same
meaning as a “Transfer of Control” as defined in the Plan.

     For the purposes of this offer letter agreement, “Good Reason” will mean, without your
consent: (i) a reduction of your Base Salary or Target Bonus below the amounts set forth in this
offer letter agreement; (ii) a material reduction in the aggregate benefits provided in this offer
letter agreement; provided, however, that if such reduction is part of a reduction generally
applicable to the Company’s senior executives, it shall not constitute Good Reason; (iii) any
reduction in your title, (iv) a material reduction in your duties or responsibilities; provided,
however, that so long as you remain the Chief Executive Officer and President of the Company
following a Change of Control in which neither the Company’s nor its acquirer’s equity securities
are publicly traded on an established national securities market, the reduction in your duties and
responsibilities as a result of such a going private transaction shall not in and of itself
constitute Good Reason, or (iv) requiring you to relocate to a location more than thirty-five (35)

 

 

miles from your then current office location, provided, however, that Good Reason shall not exist
unless you have provided the Company with written notice of the purported grounds for such Good
Reason and such purported grounds are not cured within thirty (30) days of the Company’s receipt of
such written notice.

     The receipt of any severance or other benefits pursuant to this offer letter agreement will be
subject to you agreeing that during the Employment Term and for a period of eighteen (18) months
following the termination of your employment, you will not: (i) solicit any employee or consultant
of the Company for employment other than at the Company, or (ii) directly or indirectly engage in,
have any ownership interest in or participate in any entity that as of the date of termination,
competes with the Company in any substantial business of the Company or any business reasonably
expected to become a substantial business of the Company.

     Subject to applicable law, you will be provided indemnification to the maximum extent
permitted by the Company’s Articles of Incorporation or Bylaws, including, if applicable, any
directors and officers insurance policies, with such indemnification to be on terms determined by
the Board or any of its committees, but on terms no less favorable than provided to any other
Company executive officer or director and subject to the terms of any separate written
indemnification agreement.

     You agree that any dispute or controversy arising out of, relating to, or in connection with
this offer letter agreement, or the interpretation, validity, construction,
performance, breach, or termination thereof, will be finally settled by binding arbitration to be
held in Dallas, Texas under the American Arbitration Association National Rules for the Resolution
of Employment Disputes, supplemented by the Texas Rules of Civil Procedure, as then in effect (the
“Rules”). The arbitrator(s) may grant injunctions or other relief in such dispute or controversy.
The decision of the arbitrator(s) will be final, conclusive and binding on the parties to the
arbitration, and judgment may be entered on the decision of the arbitrator(s) in any court having
jurisdiction. The Company will pay the costs and expenses of such arbitration, and each party will
pay its own counsel fees and expenses.

     This offer letter agreement will be governed by and construed in accordance with the internal
substantive laws, but not the choice of law rules, of the State of Texas. You hereby consent to
the personal jurisdiction of the state and federal courts located in Texas for any action or
proceeding arising from or relating to this offer letter agreement or relating to any arbitration
in which you and the Company are participants.

     The Company will reimburse you up to $15,000 for reasonable and actual legal expenses incurred
by you in connection with the negotiation, preparation and execution of this offer letter
agreement.

     You and the Company agree to work together in good faith to consider amendments to this offer
letter agreement necessary or appropriate to avoid imposition of any additional tax or income
recognition to you under Internal Revenue Code Section 409A and the proposed or final regulations
issued thereunder.

     Enclosed is a copy of our standard Proprietary Information Agreement. This offer of
employment is contingent on you executing this Proprietary Information Agreement and upon

 

 

     the satisfactory completion of a background check in accordance with the Company’s policy.

     If you wish to accept employment at the Company under the terms set out above, please sign and
date this letter and return it to me no later than March 9, 2007, keeping a copy for your records.

We look forward to your leading the McAfee team!

	 	 	 	 	 
	 	Sincerely,

/s/ Charles J. Robel

Charles J. Robel

Chairman of the Board

 	 
	 	 	 
	 	 	 
	 	 	 
	 

     I have read and accept the above:

	/s/ Dave DeWalt	 	3/5/07
	 

	 	 
	Signature

	 	Date Signed

	4/2/07	 	 
	 

	 	 
	Start Dateexv10w59

 

EXHIBIT 10.59

PATENT AND TECHNOLOGY LICENSE AGREEMENT

     This thirty-one (31) page AGREEMENT (“AGREEMENT”) is made on this 30th day of
September, 2006, by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM
(“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street,
Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”),
a component institution of SYSTEM, and Introgen Therapeutics, Inc., a Texas corporation having a
principal place of business located at 301 Congress, Suite 1850, Austin, Texas 78701 (“LICENSEE”).

RECITALS

	A.	 	BOARD owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED SUBJECT MATTER
developed at UTMDACC.
	 
	B.	 	BOARD, through UTMDACC, desires to have the LICENSED SUBJECT MATTER developed in the LICENSED
FIELD and used for the benefit of LICENSEE, BOARD, SYSTEM, UTMDACC, the inventor(s), and the
public as outlined in BOARD’s Intellectual Property Policy.
	 
	C.	 	LICENSEE wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER.
	 
	 	 	NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the
parties agree as follows:

I. EFFECTIVE DATE

	1.1	 	This AGREEMENT is effective as of the date first listed above (“EFFECTIVE DATE”).

1

 

II. DEFINITIONS

	 	 	As used in this AGREEMENT, the following terms have the meanings indicated:

	2.1	 	AFFILIATE means any business entity more than fifty percent (50%) owned by LICENSEE, any
business entity which owns more than fifty percent (50%) of LICENSEE, or any business entity
that is more than fifty percent (50%) owned by a business entity that owns more than fifty
percent (50%) of LICENSEE.
	 
	2.2	 	LICENSED FIELD means [*].
	 
	2.3	 	LICENSED PRODUCTS means any product or service sold by LICENSEE, its AFFILIATES or
SUBLICENSEES comprising LICENSED SUBJECT MATTER pursuant to this AGREEMENT.
	 
	2.4	 	LICENSED SUBJECT MATTER means inventions and discoveries covered by PATENT RIGHTS or
TECHNOLOGY RIGHTS within LICENSED FIELD.
	 
	2.5	 	LICENSED TERRITORY means [*].
	 
	2.6	 	MAJOR MARKET COUNTRIES means, collectively, all of the United States, Japan and at least four
of the following countries in Europe: United Kingdom, France, Germany, Spain, Italy, Sweden
and Switzerland.
	 
	2.7	 	NET SALES means the gross revenues received by LICENSEE, its AFFILIATES or SUBLICENSEES from
a SALE less sales discounts actually granted, sales and/or use taxes actually paid, import
and/or export duties actually paid, outbound transportation actually prepaid or allowed, and
amounts actually allowed or credited due to returns (not exceeding the original billing or
invoice amount), all as recorded by LICENSEE, AFFILIATES or SUBLICENSEES in their official
books and records in accordance with generally accepted

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-2-

 

	 	 	accounting practices and consistent with their published financial statements and/or
regulatory filings with the United States Securities and Exchange Commission.

	2.8	 	PATENT RIGHTS means (a) all of BOARD’s rights in and to any patents and patent applications,
whether domestic or foreign, that claim any invention, information or discovery described in
any of the invention disclosures defined in Exhibit I attached hereto, including the patent
application listed in Exhibit I, and all patents, whether domestic or foreign that issue
thereon; and (b) all divisionals, continuations, continuations-in-part (to the extent the
claims of such continuations-in-part are entitled to claim priority to the aforesaid patents
and/or patent applications defined in clause (a)), reissues, reexaminations or extensions of
the patents and patent applications defined in clause (a), and any letters patent, domestic or
foreign that issue thereon. From time to time during the term of this AGREEMENT, upon request
by either party, LICENSEE and BOARD shall promptly update Exhibit I to include all patent
applications and patents that are within PATENT RIGHTS.
	 
	2.9	 	SALE or SOLD means the transfer or disposition of a LICENSED PRODUCT for value (or, with
respect to LICENSED PRODUCTS that are services, the provision of such services for value on a
fee-for-services basis) to a party other than LICENSEE, an AFFILIATE or a ROYALTY-FREE
PRACTITIONER. As used herein, “ROYALTY-FREE PRACTITIONER” means UTMDACC and Jack Roth, M.D. (
the “PHYSICIAN INVENTOR”), and any partner or associate who practices medicine with one or
more of the PHYSICIAN INVENTOR, but with respect to such partner or associate, only for such
time as they are engaged in a bona fide medical practice with one or more of the PHYSICIAN
INVENTOR.

-3-

 

	2.10	 	SUBLICENSEE means any third party to whom LICENSEE has granted a sublicense under the
LICENSED SUBJECT MATTER to make and sell LICENSED PRODUCTS, with respect to LICENSED PRODUCTS
made and sold by such SUBLICENSEE. As used herein, “SUBLICENSEE” shall also mean a third party
to whom LICENSEE has granted the exclusive right to distribute LICENSED PRODUCTS supplied by
LICENSEE, provided that such third party is responsible for all marketing and promotion of the
subject LICENSED PRODUCTS within its exclusive territory.
	 
	2.11	 	SUBLICENSE INCOME means all consideration received by LICENSEE from a SUBLICENSEE in
consideration of a sublicense of the LICENSED SUBJECT MATTER, including but not limited to,
up-front payments, marketing, distribution, franchise, option, license, or documentation fees,
bonus and milestone payments and equity securities. SUBLICENSE INCOME shall specifically
exclude: (i) payments received by LICENSEE from a sublicense as a result of the purchase or
sale of debt or equity securities of LICENSEE by such sublicense, and (ii) payments for
research and development of the LICENSED PRODUCTS; and (iii) any royalties that LICENSEE
receives for the SUBLICENSEE’S sale of LICENSED PRODUCTS (which are captured under Section 4.1
(d)).
	 
	2.12	 	TECHNOLOGY RIGHTS means BOARD’S rights in any technical information, knowhow, processes,
procedures, compositions, devices, methods, formulae, protocols, techniques, software,
designs, drawings or data created by the inventor(s) listed in Exhibit I, or those working in
the lab or under the supervision or direction of one or more of the inventor(s) listed in
Exhibit I, at UTMDACC before the EFFECTIVE DATE, whether or not

-4-

 

	 	 	claimed in PATENT RIGHTS but that are reasonably necessary for practicing an invention at
any time claimed in the PATENT RIGHTS.

	2.13	 	VALID CLAIM means either (a) a claim of an issued and unexpired patent included within the
PATENT RIGHTS which has not been held unenforceable, unpatentable or invalid by the final
decision of a court or other governmental agency of competent jurisdiction, in which such
decision is unappealable or unappealed within the time allowable for appeal, and which has not
been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b)
a pending claim in a patent application within the PATENT RIGHTS, provided that if such
pending claim has not issued as a claim or an issued patent within the PATENT RIGHTS within
five (5) years after the filing of the application in which such claim first appears, such
pending claim shall not be a VALID CLAIM for purposes of this AGREEMENT, unless and until
subsequent to such five (5) year period, such pending claim is issued as a claim of an issued
and unexpired patent included within the PATENT RIGHTS as set forth in (a) above.

III. LICENSE

	3.1	 	BOARD, through UTMDACC, hereby grants to LICENSEE a [*] license under LICENSED SUBJECT MATTER
to [*] LICENSED PRODUCTS, to [*] the LICENSED SUBJECT MATTER, in each case within LICENSED
TERRITORY for use within LICENSED FIELD. This grant is subject to Sections 14.2 and 14.3
herein below, the payment by LICENSEE to UTMDACC of all consideration as provided herein, and
is further subject to the following rights retained by BOARD and UTMDACC to:

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-5-

 

	 	(a)	 	Publish the general, scientific findings from research related to LICENSED
SUBJECT MATTER, subject to the terms of Article XI-Confidential Information and
Publication; and
	 
	 	(b)	 	Use LICENSED SUBJECT MATTER for research, teaching, patient care, and other
educationally-related purposes; and
	 
	 	(c)	 	Transfer LICENSED SUBJECT MATTER to academic or research institutions for
non-commercial research use.

	3.2	 	LICENSEE may extend the license granted herein to any AFFILIATE provided that the AFFILIATE
consents in writing to be bound by this AGREEMENT to the same extent as LICENSEE. LICENSEE
agrees to deliver such contract to UTMDACC within thirty (30) calendar days following
execution thereof.
	 
	3.3	 	LICENSEE may grant and authorize sublicenses under LICENSED SUBJECT MATTER consistent with
the terms of this AGREEMENT. LICENSEE is responsible to use commercially reasonable efforts to
cause its SUBLICENSEES to comply with the relevant obligations under this AGREEMENT, and for
diligently collecting all amounts due LICENSEE from SUBLICENSEES. If a SUBLICENSEE pursuant
hereto becomes bankrupt, insolvent or is placed in the hands of a receiver or trustee,
LICENSEE, to the extent allowed under applicable law and in a timely manner, agrees to use its
reasonable efforts to collect all consideration owed to LICENSEE and to have the sublicense
agreement confirmed or rejected by a court of proper jurisdiction.
	 
	3.4	 	LICENSEE must deliver to UTMDACC a true and correct copy of each sublicense granted by
LICENSEE, and any modification or termination thereof, within thirty (30) calendar days after
execution, modification, or termination.

-6-

 

	3.5	 	If this AGREEMENT is terminated pursuant to Article XIII-Term and Termination, all
sublicenses granted hereunder that are in compliance with their terms shall survive the
termination provided that each such SUBLICENSEE consents in writing to be bound directly to
BOARD and UTMDACC to all of the terms and conditions of this AGREEMENT, subject to any field
of use or jurisdictional limitations provided in the original sublicense; provided that in
such case the SUBLICENSEE’S obligation to pay the costs of searching, preparing, filing,
prosecuting and maintaining the LICENSED SUBJECT MATTER would, notwithstanding Article XI, be
limited to a percentage of such costs based on the number of licensees of such LICENSED
SUBJECT MATTER. For example, if there were four licensees, the percentage would be 25%.

IV. CONSIDERATION, PAYMENTS AND REPORTS

	4.1	 	In consideration of rights granted by BOARD to LICENSEE under this AGREEMENT, LICENSEE agrees
to pay UTMDACC the following:

	 	(a)	 	All [*], for so long as, and in such countries as this AGREEMENT remains in
effect. UTMDACC will invoice LICENSEE after the AGREEMENT has been fully executed by
all parties for expenses incurred as of that time and on a quarterly basis thereafter.
The invoiced amounts will be due and payable by LICENSEE within thirty (30) calendar
days of invoice; and
	 
	 	(b)	 	a [*] fee in the amount of [*]. This fee will not reduce the amount of any
other payment provided for in this ARTICLE IV, and is due and payable within thirty
(30) calendar days after the AGREEMENT has been fully executed by all parties and
LICENSEE has received an invoice for the amount from UTMDACC; and
	 
	 	(c)	 	[*] due and payable as follows until the first SALE:

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-7-

 

	 	§	 	First, second and third anniversary of the EFFECTIVE DATE: [*];
	 
	 	§	 	Fourth, fifth sixth and seventh anniversary of the EFFECTIVE
DATE: [*];
	 
	 	§	 	Eighth and all subsequent anniversaries of the EFFECTIVE DATE
until first SALE: [*] (collectively, the “Annual Maintenance Fee”).

	 	The Annual Maintenance Fees will be due without invoice within thirty (30) days of
each anniversary of the EFFECTIVE DATE until first SALE and will not reduce the
amount of any other payment provided for in this ARTICLE IV; and

	(d)	 	A running royalty equal to [*] attributed to SALES of LICENSED PRODUCTS by
LICENSEE, AFFILIATES and SUBLICENSEES, subject to the following:

	 	§	 	It is understood that royalties shall be
due under this Section 4.l(d) above only on SALES of LICENSED PRODUCTS,
the SALE of which would, but for the license granted herein, infringe a
VALID CLAIM in the country for which such LICENSED PRODUCT is SOLD.
However, if the SALE of a LICENSED PRODUCT would infringe a VALID CLAIM
in the MAJOR MARKET COUNTRIES, LICENSEE shall pay royalties hereunder on
all sales of such LICENSED PRODUCT in any country, regardless of whether
the sale of such product in such country would infiinge a VALID CLAIM.
	 
	 	§	 	In the event that more than one patent
within the PATENT RIGHTS is applicable to any LICENSED PRODUCT subject
to royalties under this Section 4.l(d), then only one royalty shall be
paid to UTMDACC in respect of such quantity of the LICENSED PRODUCTS and
in any event

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-8-

 

	 	 	 	no more than one royalty will be payable hereunder with respect to any
particular LICENSED PRODUCT unit;

	 	§	 	No royalty shall be payable under this
Section 4.1 (d) with respect to the SALE of LICENSED PRODUCTS between or
among LICENSEE, AFFILIATES and SUBLICENSEES, provided that such LICENSED
PRODUCTS are to be resold to unrelated third parties, or with respect to
any fees or other payments paid between or among LICENSEE and
AFFILIATES; nor shall a royalty be payable under this Section 4. 1(d)
with respect to SALES of LICENSED PRODUCTS for use in clinical trials or
as samples;
	 
	 	§	 	In the event that a LICENSED PRODUCT is
sold in combination as a single product, or in a kit, with another
product or component and no royalty would be due hereunder on the sale
of such other product or component alone, then NET SALES from such
combination sales for purposes of calculating the amounts due under this
Section 4.l(d) shall be as reasonably allocated, as determined in good
faith by LICENSEE and UTMDACC, between such LICENSED PRODUCT and such
other product or components, based upon their relative importance and
proprietary protection as commercially reasonable;
	 
	 	§	 	To the extent that the LICENSEE is
required, by order or judgment of any court to obtain in any
jurisdiction any license from a third party in order to practice the
rights granted to the LICENSEE hereunder, or LICENSEE otherwise
reasonably determines that such a license is necessary, then up to [*]
may be deducted from royalties otherwise payable to UTMDACC

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-9-

 

	 	 	 	from the LICENSEE in that jurisdiction, provided that in no event shall
the royalties payable to UTMDACC pursuant to this Section 4.l(d) in any
quarterly period in such jurisdiction be reduced by [*]; and
	 
	 	§	 	Notwithstanding the foregoing, if SALES of
a LICENSED PRODUCT subject to royalty obligations under this Section
4.l(d) are also subject to a royalty under one or more other agreements
entered into by Introgen Therapeutics, Inc. and UTMDACC, LICENSEE may
reduce the royalties payable hereunder by fifty percent (50%) with
respect to SALES of such LICENSED PRODUCT. To the extent such other
agreements do not provide for a corresponding fifty percent (50%)
reduction in the royalties payable thereunder to account for royalties
payable under this AGREEMENT, they shall by this AGREEMENT be deemed
amended to provide for such corresponding fifty percent (50%) reduction
in the royalties payable thereunder; and

	(e)	 	After first SALE, minimum annual royalties of [*]. This amount shall be due
and payable within thirty (30) days of the first and all subsequent anniversaries of
the EFFECTIVE DATE which follows the first SALE (“Minimum Annual Royalties”); provided,
however, that in the event that there is less than a twelve month period between the
first SALE and the first anniversary of the EFFECTIVE DATE which follows the first
SALE, then LICENSEE shall pay the following: (1) the Annual Maintenance Fee due for
that year multiplied by the fraction, A/C, where A is the number of months between the
anniversary of the EFFECTIVE DATE preceding the first SALE and the first SALE and C is
twelve (12); and (2) the Minimum Annual

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-10-

 

	 	 	Royalty multiplied by the fraction B/C, where B is the number of months between the
first SALE and the first anniversary of the EFFECTIVE DATE which follows the first
SALE, C is twelve and A + B = twelve (12). Additionally, running royalties accrued
under Section 4.l(d) and paid to UTMDACC during the one year period preceding an
anniversary of the EFFECTIVE DATE shall be credited against the Minimum Annual
Royalties due on that anniversary date; and

	 	(f)	the following percentage of SUBLICENSE INCOME received by LICENSEE:

	 	§	 	[*] of SUBLICENSE INCOME received by the
LICENSEE from the EFFECTIVE DATE until the [*] anniversary thereof; and
	 
	 	§	 	[*] of SUBLICENSEE INCOME received by
LICENSEE on and after the [*] anniversary of the EFFECTIVE DATE until
the termination or expiration of this AGREEMENT.

	 	 	 	Additionally, the maximum payment to UTMDACC under this Section 4.l(f) for each
sublicense agreement is [*].

	4.2	 	Unless otherwise provided, all such payments are payable within thirty (30) calendar days
after March 31, June 30, September 30, and December 31 of each year during the term of this
AGREEMENT, at which time LICENSEE will also deliver to UTMDACC a true and accurate report,
giving such particulars of the business conducted by LICENSEE, its AFFILIATES and its
SUBLICENSEES, if any exist, during the preceding three (3) calendar months under this
AGREEMENT as necessary for UTMDACC to account for LICENSEE’s payments hereunder. This report
will include pertinent data, including, but not limited to:

	 	(a)	 	the accounting methodologies used to account for and calculate the items
included in the report and any differences in such accounting methodologies used by
LICENSEE since the previous report; and

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-11-

 

	 	(b)	 	a list of LICENSED PRODUCTS produced for the three (3) preceding calendar
months; and
	 
	 	(c)	 	the total quantities of LICENSED PRODUCTS produced; and
	 
	 	(d)	 	the total SALES; and
	 
	 	(e)	 	the calculation of NET SALES; and
	 
	 	(f)	 	the royalties so computed and due UTMDACC and/or minimum royalties; and
	 
	 	(g)	 	all SUBLICENSING INCOME received from each SUBLICENSEE and payments due UTMDACC
under Section 4.l(f); and
	 
	 	(h)	 	all other amounts due UTMDACC herein.

	 	Simultaneously with the delivery of each such report, LICENSEE agrees to pay UTMDACC the
amount due, if any, for the period of such report. These reports are required even if no
payments are due.

	4.3	 	During the term of this AGREEMENT and for one (1) year thereafter, LICENSEE agrees to keep
complete and accurate records of its, its AFFILIATES’ and its SUBLICENSEES’ SALES and NET
SALES in sufficient detail to enable the royalties and other payments due hereunder to be
determined. LICENSEE agrees to permit UTMDACC or its representatives, at UTMDACC’s expense,
to periodically examine LICENSEE’S books, ledgers, and records during regular business hours
for the purpose of and to the extent necessary to verify any report required under this
AGREEMENT. If any amounts due UTMDACC are determined to have been underpaid in an amount
equal to or greater than five percent (5%) of the total amount due during the period so
examined, then LICENSEE will pay the cost of the examination plus accrued interest at the
highest allowable rate.

	4.4	 	Within thirty (30) calendar days following each anniversary of the EFFECTIVE DATE, LICENSEE
will deliver to UTMDACC a written progress report as to LICENSEE’S (and

-12-

 

	 	 	any SUBLICENSEE’s) efforts and accomplishments during the preceding year in diligently
commercializing LICENSED SUBJECT MATTER in the LICENSED TERRITORY and LICENSEE’s (and
SUBLICENSEE’s) commercialization plans for the upcoming year.
	 
	4.5	 	All amounts payable hereunder by LICENSEE will be paid in United States funds without
deductions for taxes, assessments, fees, or charges of any kind. Checks are to be made payable
to The University of Texas M. D. Anderson Cancer Center, and sent by United States mail to Box
297402, Houston, Texas 77297, Attention: Grants and Contracts or by wire transfer to:
	 
	 	 	[*]
	 
	4.6	 	No payments due or royalty rates owed under this AGREEMENT will be reduced as the result of
co-ownership of LICENSED SUBJECT MATTER by BOARD and LICENSEE.

V. SPONSORED RESEARCH

	5.1	 	If LICENSEE desires to sponsor research for or related to the LICENSED SUBJECT MATTER, and
particularly where LICENSEE receives payments for sponsored research pursuant to a sublicense
under this AGREEMENT, LICENSEE (a) will notify UTMDACC in writing of all opportunities to
conduct this sponsored research (including clinical trials, if applicable), (b) will solicit
research and/or clinical proposals from UTMDACC for this purpose, and (c) will give good faith
consideration to funding the proposals at UTMDACC.

VI. PATENTS AND INVENTIONS

	6.1	 	If after consultation with LICENSEE both parties agree that a new patent application should
be filed for LICENSED SUBJECT MATTER, UTMDACC will prepare and file appropriate patent
applications, and LICENSEE will pay the cost of searching, preparing, filing, prosecuting and
maintaining same. If LICENSEE notifies UTMDACC that it does not intend

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-13-

 

	 	 	to pay the cost of an application, or if LICENSEE does not respond or make an effort to
agree with UTMDACC on the disposition of rights of the subject invention, then UTMDACC may
file such application at its own expense and LICENSEE’S rights to such application under
this AGREEMENT shall terminate in their entirety; provided, however, that if LICENSEE files
and maintains patents in the MAJOR MARKET COUNTRIES, UTMDACC may not terminate LICENSEE’S
rights to applications filed in other jurisdictions. UTMDACC will provide LICENSEE with a
copy of the application for which LICENSEE has paid the cost of filing, as well as copies of
any documents received or filed during prosecution thereof. UTMDACC shall consult with
LICENSEE in a timely manner concerning (i) scope and content of all patent applications
within the PATENT RIGHTS prior to filing such patent applications, and (ii) content of and
proposed responses to official actions of the United States Patent and Trademark Office and
foreign patent offices during prosecution of any patent applications within the PATENT
RIGHTS. For purposes of this Paragraph 6.1, “timely” shall mean sufficiently in advance of
any decision by UTMDACC or any deadline imposed upon written response by UTMDACC so as to
allow LICENSEE to meaningfully review such decision or written response and also provide
comments to UTMDACC in advance of such decision or deadline to allow comments of LICENSEE
respect to the PATENT RIGHTS to be considered and incorporated into UTMDACC’s decision or
written response. The parties agree that they share a common legal interest to get valid
enforceable patents and that LICENSEE will keep all privileged information received pursuant
to this Section confidential.
	 
	6.2	 	With respect to the filing of any patent application within the PATENT RIGHTS, or the
prosecution of any patent application within the PATENT RIGHTS, or the maintenance of any
patent within the PATENT RIGHTS, if UTMDACC elects not to file for or continue

-14-

 

	 	 	prosecution of any such patent application or maintain any such patent, UTMDACC shall
promptly notify LICENSEE in writing sufficiently in advance of any deadline to enable
LICENSEE to file for or continue prosecution of such patent application and/or maintain such
patent, and in such event LICENSEE (or its. designee) may at its discretion pursue such
filing, prosecution and/or maintenance of its own expense in UTMDACC’s name.

VII. INFRINGEMENT BY THIRD PARTIES

	7.1	 	LICENSEE, at its expense, shall use commercially reasonable efforts to enforce any patent
exclusively licensed hereunder against substantial and continuing infringement by third
parties and is entitled to retain recovery from such enforcement. It is understood, however,
that such obligation shall not be deemed to require LICENSEE to take such actions with respect
to each such infringement, and LICENSEE may take into account reasonable strategic and other
considerations in determining which infringers to take action against, as well as when and
whether to do so. After reimbursement of LICENSEE’s reasonable legal costs and expenses
related to such recovery, LICENSEE agrees to pay a percentage of the monetary recovery it
receives to UTMDACC, such percentage to be equal to the percentage that would apply under
Section 4.1 if such monetary recovery was considered SUBLICENSE INCOME under this AGREEMENT;
provided that for any monetary recovery that is for sales of LICENSED PRODUCTS lost to the
infringement, in no event shall LICENSEE be responsible to pay UTMDACC amounts in excess of
the royalty detailed in Section 4.l(d) for such lost sales. LICENSEE must notify UTMDACC in
writing of any material potential infringement within thirty (30) calendar days of knowledge
thereof. If within twelve (12) months of a request by UTMDACC to file suit, LICENSEE does not
file suit against a third party that UTMDACC and LICENSEE mutually agree is a substantial
infringer and that

-15-

 

	 	 	enforcement would be in the best interest of the licensed products (such agreement not to be
unreasonably withheld), or where there is a good-faith dispute on the matter, it is so
determined pursuant to the dispute-resolution procedures of Section 15.6 below, then BOARD
or UTMDACC may, at its sole discretion, enforce any patent licensed hereunder against the
infringing activities of such infringer, with UTMDACC retaining [*] of all recoveries from
such enforcement after reimbursement of UTMDACC’s reasonable legal costs and expenses
related to such recovery; provided LICENSEE shall always have the option to jointly
participate in such enforcement action, including, at LICENSEE’s discretion, by jointly
bringing the action with UTMDACC or joining as a party plaintiff. If LICENSEE joins such
suit and shares in the legal costs and expenses of the enforcement, then any recovery from
such enforcement shall be shared by the parties [*]; provided that in no event shall UTMDACC
retain more than [*] of any recovery after reimbursement of legal costs.
	 
	7.2	 	In any suit or dispute involving an infringer, the parties agree to cooperate fully with each
other. At the request and expense of the party bringing suit, the other party will permit
reasonable access during regular business hours, to all relevant personnel, records, papers,
information, samples, specimens, and the like in its possession, and where LICENSEE is the
party bringing the suit, BOARD and UTMDACC will, subject to the statutory authority of the
Attorney General of the State of Texas, join the suit as a party plaintiff and sign all
documents necessary to do so.

VIII. PATENT MARKING

	8.1	 	LICENSEE agrees that all packaging containing individual LICENSED PRODUCT(S), documentation
therefor, and, when possible, actual LICENSED PRODUCT(S) sold by LICENSEE, AFFILIATES, and/or
SUBLICENSEES of LICENSEE will be permanently and

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-16-

 

	 	 	legibly marked with the number of any applicable patent(s) licensed hereunder in accordance
with each country’s patent laws, including Title 35, United States Code.

IX. INDEMNIFICATION AND INSURANCE

	9.1	 	LICENSEE agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC, their Regents,
officers, employees, students and agents from and against any claims, demands, or causes of
action whatsoever, costs of suit and reasonable attorney’s fees, including without limitation,
those costs arising on account of any injury or death of persons or damage to property caused
by, or arising out of, or resulting from, the exercise or practice of the rights granted
hereunder by LICENSEE, its officers, its AFFILIATES or their officers, employees, agents or
representatives.
	 
	9.2	 	In no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect, special, consequential
or punitive damages (including, without limitation, damages for loss of profits or expected
savings or other economic losses, or for injury to persons or property) arising out of, or in
connection with, this AGREEMENT or its subject matter, regardless of whether BOARD, SYSTEM or
UTMDACC knows or should know of the possibility of such damages.
	 
	9.3	 	Beginning at the time when any LICENSED SUBJECT MATTER is being distributed or sold
(including for the purpose of obtaining regulatory approvals) by LICENSEE, an AFFILIATE, or by
a SUBLICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain commercial
general liability insurance in amounts not less than [*] and LICENSEE shall use reasonable
efforts to have the BOARD, SYSTEM, UTMDACC, their Regents, officers, employees, students and
agents named as additional insureds. Such commercial general liability insurance shall
provide: (i) product liability coverage; (ii) broad

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-17-

 

	 	 	form contractual liability coverage for LICENSEE’s indemnification under this AGREEMENT; and
(iii) coverage for litigation costs. The minimum amounts of insurance coverage required
herein shall not be construed to create a limit of LICENSEE’S liability with respect to its
indemnification under this AGREEMENT.
	 
	9.4	 	LICENSEE shall provide UTMDACC with written evidence of such insurance within thirty (30)
calendar days of its procurement. Additionally, LICENSEE shall provide UTMDACC with written
notice of at least fifteen (15) calendar days prior to the cancellation, non-renewal or
material change in such insurance.
	 
	9.5	 	LICENSEE shall maintain such commercial general liability insurance beyond the expiration or
termination of this AGREEMENT during: [*].

X. USE OF BOARD AND UTMDACC’S NAME

	10.1	 	LICENSEE will not use the name of (or the name of any employee of) UTMDACC, SYSTEM or BOARD
in any advertising, promotional or sales literature, on its Web site, or for the purpose of
raising capital without the advance express written consent of BOARD secured through:

The University of Texas

M. D. Anderson Cancer Center

Legal Services, Unit 0537

P.O. Box 301439

Houston, TX 77230- 1439

ATTENTION: Natalie Wright

Email: nwright@mdanderson.org

	 	 	Notwithstanding the above, LICENSEE may use the name of (or name of employee of) UTMDACC,
SYSTEM or BOARD in routine business correspondence, or as needed in appropriate regulatory
submissions without express written consent, including when

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-18-

 

	 	 	indicating, as a factual matter, that UTMDACC, SYSTEM or BOARD is a licensor of LICENSEE
under this AGREEMENT in connection with either or both of the following:

	 	(a)	 	communications associated with LICENSEE’s financing activities; and
	 
	 	(b)	 	communications (other than promotions and advertisements) directed to
describing or responding to inquiries concerning the business, technology, products,
services and associated activities of LICENSEE.

XI. CONFIDENTIAL INFORMATION AND PUBLICATION

	11.1	 	UTMDACC and LICENSEE each agree that all information contained in documents marked
“confidential” and forwarded to one by the other (i) are to be received in strict confidence,
(ii) are to be used only for the purposes of this AGREEMENT, and (iii) will not be disclosed
by the recipient party (except as required by law or court order), its agents or employees
without the prior written consent of the disclosing party, except to the extent that such
information:

	 	(a)	 	was in the public domain at the time of disclosure; or
	 
	 	(b)	 	later became part of the public domain through no act or omission of the
recipient party, its employees, agents, successors or assigns; or
	 
	 	(c)	 	was lawfully disclosed to the recipient party by a third party having the right
to disclose it; or
	 
	 	(d)	 	was already known by the recipient party at the time of disclosure, as
demonstrated by competent written proof (such as contemporaneous records); or
	 
	 	(e)	 	was independently developed by the recipient party without use of the
disclosing party’s confidential information, as demonstrated by competent written proof
(such as contemporaneous records); or
	 
	 	(f)	 	is required by law or regulation to be disclosed.

-19-

 

	 	 	Notwithstanding the foregoing, LICENSEE may disclose any LICENSED SUBJECT MATTER comprising
the confidential information of UTMDACC to third parties pursuant to a commercially
reasonable confidentiality agreement, or otherwise in connection with the exercise of its
license rights under this AGREEMENT.
	 
	11.2	 	Each party’s obligation of confidence hereunder will be fulfilled by using at least the same
degree of care with the disclosing party’s confidential information as it uses to protect its
own confidential information, but always at least a reasonable degree of care. This
obligation will exist while this AGREEMENT is in force and for a period of three (3) years
thereafter.
	 
	11.3	 	UTMDACC reserves the right to [*]. UTMDACC will submit [*] to LICENSEE at least thirty (30)
calendar days before [*] and LICENSEE shall have the right to [*] in order to protect
LICENSEE’s confidential information. Upon LICENSEE’s request, publication may be delayed up
to sixty (60) additional calendar days to enable LICENSEE to secure adequate intellectual
property protection of LICENSEE’s confidential information that would otherwise be affected by
[*].

XII. ASSIGNMENT

	12.1	 	Except in connection with the sale of all or substantially all of LICENSEE’S business or
assets relating to this AGREEMENT to a third party, this AGREEMENT may not be assigned by
LICENSEE without the prior written consent of UTMDACC, which will not be unreasonably
withheld.

XIII. TERM AND TERMINATION

	13.1	 	Subject to Sections 13.3 and 13.4 hereinbelow, the term of this AGREEMENT is from the
EFFECTIVE DATE to [*].

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-20-

 

	13.2	 	Any time after [*] from the EFFECTIVE DATE, BOARD or UTMDACC have the right to terminate the
exclusivity of this license in any national political jurisdiction within the LICENSED
TERRITORY if LICENSEE, within ninety (90) calendar days after receiving written notice from
UTMDACC of the intended termination, fails to provide reasonable written evidence that
LICENSEE or its SUBLICENSEE(s) has commercialized or is actively and effectively attempting to
commercialize a licensed invention in such jurisdiction(s), provided that if LICENSEE or its
SUBLICENSEE(s) .has commercialized or is actively and effectively attempting to commercialize
a licensed invention within any of the United States, Japan or any MAJOR MARKET COUNTRY in
Europe, LICENSEE shall be considered to have satisfied its obligations under this Section 13.2
worldwide. The following definitions apply to Section 13.2: (a) “commercialized” means having
SALES in such jurisdiction; and (b) “actively and effectively attempting to commercialize”
means having an ongoing and active research, development, manufacturing, marketing or sales
program as appropriate, directed toward developing, obtaining regulatory approval, and/or
production and/or SALES in any jurisdiction.
	 
	13.3	 	Subject to any rights herein which survive termination, this AGREEMENT will earlier terminate
in its entirety:

	 	(a)	 	automatically, if LICENSEE becomes bankrupt and/or if the business of LICENSEE
shall be placed in the hands of a receiver, assignee, or trustee, whether by voluntary
act of LICENSEE or otherwise; or
	 
	 	(b)	 	upon thirty (30) calendar days written notice from UTMDACC, if LICENSEE
breaches or defaults on the payment or report obligations of ARTICLE IV, or use of name
obligations of ARTICLE X, unless, before the end of the such thirty (30) calendar day

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-21-

 

	 	 	 	notice period, LICENSEE has cured the default or breach, and so notifies UTMDACC,
stating the manner of the cure; or
	 
	 	(c)	 	upon ninety (90) calendar days written notice from UTMDACC if LICENSEE breaches
or defaults on any other material obligation under this AGREEMENT, unless, before the
end of the such ninety (90) calendar-day notice period, LICENSEE has cured the default
or breach and so notifies UTMDACC, stating the manner of the cure; or
	 
	 	(d)	 	at any time by mutual written agreement between LICENSEE and UTMDACC upon one
hundred eighty (180) calendar days written notice to all parties and subject to any
terms herein which survive termination.

	 	 	Notwithstanding the foregoing, if before the end of the applicable cure period of
Section13.3(b) or (c) above, LICENSEE disputes the breach or default claimed by UTMDACC,
UTMDACC shall not have the right to terminate this AGREEMENT unless and until the parties
have completed the dispute resolution procedure outlines in Section 15.6, LICENSEE is found
to have materially breached this AGREEMENT, and LICENSEE fails to cure such breach within
the applicable cure period following such determination; provided that the foregoing shall
not suspend any obligation of LICENSEE to pay to UTMDACC any undisputed amount owed by
LICENSEE to UTMDACC under this AGREEMENT, during the pendency of any determination of
breach. Additionally, UTMDACC can terminate according to Section 13.3(b) above if it is for
nonpayment of patent expenses pursuant to Section 4.l(a), nonpayment of the license
documentation fee in Section 4.l(b), nonpayment of the Annual Maintenance Fees in Section
4.l(c) or nonpayment of the Minimum Annual Royalties in Section 4.1 (e).

13.4 Upon termination of this AGREEMENT:

-22-

 

	 	(a)	 	nothing herein will be construed to release either party of any obligation
maturing prior to the effective date of the termination; and
	 
	 	(b)	 	the parties covenant and agree to be bound by the provisions of Articles IX
(Indemnification and Insurance), X (Use of Board and UTMDACC’s Name) and XI
(Confidential Information and Publication) of this AGREEMENT, and any other provisions
that by their nature or as otherwise provided herein, are intended to survive this
AGREEMENT; and
	 
	 	(c)	 	LICENSEE may, for a period of [*] after the effective date of the termination,
sell all LICENSED PRODUCTS and parts therefor that it has on hand at the date of
termination, if LICENSEE pays the earned royalty thereon and any other amounts due
pursuant to Article IV of this AGREEMENT; and
	 
	 	(d)	 	Subject to Sections, 3.5, 13.1 and 13.4(c), the license granted to LICENSEE
under Section 3.1 shall terminate and LICENSEE agrees to cease and desist any use and
all SALE of the LICENSED SUBJECT MATTER and LICENSED PRODUCTS upon termination of this
AGREEMENT.

XIV. WARRANTY: SUPERIOR-RIGHTS

	14.1	 	Except for the rights, if any, of the Government of the United States of America as set forth
below, BOARD represents and warrants its belief that (a) it is the owner of the entire right,
title, and interest in and to LICENSED SUBJECT MATTER, (b) it has the sole right to grant
licenses thereunder, and (c) it has not knowingly granted licenses thereunder to any other
entity that would restrict rights granted hereunder except as stated herein.
	 
	14.2	 	LICENSEE understands that the LICENSED SUBJECT MATTER may have been developed under a funding
agreement with the Government of the United States of America

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-23-

 

	 	 	(“Government”) and, if so, that the Government may have certain rights relative thereto.
This AGREEMENT is explicitly made subject to the Government’s rights under any such
agreement and any applicable law or regulation. To the extent that there is a conflict
between any such agreement, applicable law or regulation and this AGREEMENT, the terms of
such Government agreement, applicable law or regulation shall prevail. To the extent
required by applicable law or regulation, LICENSEE agrees that LICENSED PRODUCTS used or
SOLD in the United States will be manufactured substantially in the United States, unless a
written waiver is obtained in advance from the GOVERNMENT.
	 
	14.3	 	LICENSEE understands and agrees that BOARD and UTMDACC, by this AGREEMENT, make no
representation as to the operability or fitness for any use, safety, efficacy, approvability
by regulatory authorities, time and cost of development, patentability, and/or breadth of the
LICENSED SUBJECT MATTER. BOARD and UTMDACC, by this AGREEMENT, also make no representation as
to whether any patent covered by PATENT RIGHTS is valid or as to whether there are any patents
now held, or which will be held, by others or by BOARD or UTMDACC in the LICENSED FIELD, nor
do BOARD and UTMDACC make any representation that the inventions contained in PATENT RIGHTS do
not infringe any other patents now held or that will be held by others or by BOARD.
	 
	14.4	 	LICENSEE, by execution hereof, acknowledges, covenants and agrees that LICENSEE has not been
induced in any way by BOARD, SYSTEM, UTMDACC or employees thereof to enter into this AGREEMENT

XV. GENERAL

	15.1	 	This AGREEMENT constitutes the entire and only agreement between the parties for LICENSED
SUBJECT MATTER and all other prior negotiations, representations, agreements and
understandings are superseded hereby. No agreements altering or

-24-

 

	 	 	supplementing the terms hereof will be made except by a written document signed by both
parties.
	 
	15.2	 	Any notice required by this AGREEMENT must be given by prepaid, first class, certified mail,
return receipt requested, and addressed in the case of UTMDACC to:

The University of Texas M. D. Anderson Cancer Center

Office of Technology Commercialization

7515 S. Main, Suite 490, Unit 0510

Houston, Texas 77030

ATTENTION: Christopher C. Capelli, M.D.

or in the case of LICENSEE to:

Introgen Therapeutics, Inc.

301 Congress, Suite 1850

Austin, Texas 78701

ATTENTION: David Nance

     or other addresses as may be given from time to time under the terms of this notice provision.

	15.3	 	LICENSEE must comply with all applicable federal, state and local laws and regulations in
connection with its activities pursuant to this AGREEMENT.
	 
	15.4	 	LICENSEE acknowledges that the LICENSED SUBJECT MATTER is subject to U. S. export control
jurisdiction. LICENSEE agrees to comply with all applicable international and national laws
that apply to the LICENSED SUBJECT MATTER, including U.S. Export Administration Regulations,
as well as end-user, end-use, and destination restrictions applied by the United States.
	 
	15.5	 	This AGREEMENT will be construed and enforced in accordance with the laws of the United
States of America and of the State of Texas, without regard to its conflict of law provisions.
The Texas State Courts of Harris County, Texas (or, if there is exclusive federal
jurisdiction, the United States District Court for the Southern District of Texas) shall have
exclusive jurisdiction and venue over any dispute arising out of this AGREEMENT, and

-25-

 

	 	 	LICENSEE consents to the jurisdiction of such courts; however, nothing in this AGREEMENT
shall be deemed as a waiver by BOARD, SYSTEM or UTMDACC of its sovereign immunity.

	15.6	 	Certain disputes arising out of or relating to this AGREEMENT, its construction or its actual
or alleged breach may be decided by mediation. If the mediation does not result in a
resolution of such dispute or controversy, it will be finally decided by binding arbitration,
conducted in the city of Houston, Harris County, Texas, in accordance with the applicable,
then-current procedures of the American Arbitration Association. The arbitration panel will
include members knowledgeable in the evaluation of the LICENSED SUBJECT MATTER. Judgment upon
the award rendered may be entered in the highest court or forum having jurisdiction, state or
federal. The provisions of this Section 15.6 will not apply to decisions on the validity of
patent claims or to any dispute or controversy as to which any treaty or law prohibits such
arbitration. Notwithstanding the foregoing, the decision of the arbitration must be sanctioned
by a court of law having jurisdiction to be binding upon and enforceable by the parties.
	 
	15.7	 	Failure of BOARD or UTMDACC to enforce a right under this AGREEMENT will not act as a waiver
of right or the ability to later assert that right relative to the particular situation
involved.
	 
	15.8	 	Headings included herein are for convenience only and will not be used to construe this
AGREEMENT.
	 
	15.9	 	If any part of this AGREEMENT is for any reason found to be unenforceable, all other parts
nevertheless will remain enforceable.

-26-

 

     IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to
execute this AGREEMENT.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	BOARD OF REGENTS OF THE	 	 	 	INTROGEN THERAPEUTICS, INC.
	UNIVERSITY OF TEXAS SYSTEM	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ John Mendelson M.D.
 

John Mendelsohn, M.D.
	 	 	 	By:
	 	/s/ J. David Enloe Jr.
 

J. David Enloe, Jr.
	 	 	 	 
	 

	 	President
	 	 	 	 	 	Sr. Vice President	 	 	 	 
	 	 	The University of Texas	 	 	 	Date: 9-OCT-06
	Date: 11/13/06	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	THE UNIVERSITY OF TEXAS	 	 	 	 	 	 	 	 	 	 
	M. D. ANDERSON CANCER CENTER	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Leon Leach	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Leon Leach	 	 	 	 	 	 	 	 	 	 
	 

	 	Executive Vice President	 	 	 	 	 	 	 	 	 	 
	 

	 	The University of Texas
	 	 	 	 	 	 	 	 	 	 
	 

	 	M. D. Anderson Cancer Center	 	 	 	 	 	 	 	 	 	 
	Date: 11/13/06	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Approved as to Content:	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Christopher C. Capelli	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Christopher C. Capelli	 	 	 	 	 	 	 	 	 	 
	 

	 	Vice President, Technology Transfer	 	 	 	 	 	 	 	 	 	 
	 

	 	M.D. Anderson Cancer Center	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Approved as to form:	 	 	 	 	 	 	 	 	 	 
	 

	 	/s/ NW	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	NW/LS	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Reviewed and Approved by	 	 	 	 	 	 	 	 	 	 
	UTMDACC Legal Services for	 	 	 	 	 	 	 	 	 	 
	UTMDACC Signature:	 	 	 	 	 	 	 	 	 	 
	 

	 	/s/ Illegible Signature 11/8/06	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 

-27-

 

EXHIBIT I

[*]

     [*] Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to the omitted portions.

-28-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}]]